When: $1,200+ reclaim on >3M volume with MACD bullish re-cross

Then: Add

Hold existing position. Do not add. Wait for either MACD to turn positive with price reclaiming the 50 SMA on volume, or for price to reach the primary add zone at 1050-1090 where the 200 SMA and prior consolidation provide meaningful technical support.

• RSI at 43.6 means oscillator has 13-14 points before oversold; momentum deterioration hasn't finished playing out
• ATR expanded from 25 to 39 (ATR currently 38.70), indicating higher-volatility regime than mid-summer; adding into elevated-vol environment is fighting the tape
• Stock dropped 10% in 12 trading days after fresh all-time high of 1292 on August 19
• Proposed stop at 1122 is exactly one ATR away from 1160 entry; tight stops in elevated-vol guarantee losses on routine noise
• Primary add zone at 1050-1090 sits below 200 SMA at 1057, providing structurally meaningful technical support
• Forward PEG of 0.48 using EPS of 47.23 is fragile; binary risks could cut 2027 EPS estimates by 10% to ~42, making stock 20% more expensive
• Capex of 14-15 billion is funded by debt; long-term debt rose 14B (34B to 48B) and net debt rose 10B (36B to 46B) in one year
• Stock up 76% from 52-week low; most easy money already made; next 20% requires multiple expansion or continued growth surprises, both lower probability
• Higher-for-longer rates compress present value of long-dated pipeline cash flows; LLY is a growth compounder, not low-duration value
• Active geopolitical risk: US equities falling, Treasury yields jumping, crude oil rising (Iran hostilities resuming), gold topping, crypto falling—risk-off tape in progress
• Sentiment report shows LOW confidence with retail NOT OBSERVED; bullish case is thin institutional positioning, not consensus

→ vs aggressive: Labeling the confirmed momentum reversal (RSI 43.6, MACD bearish cross, breakdown below 10 EMA/50 SMA/VWMA, lower highs/lower lows) as 'noise' is incorrect; this is momentum deterioration that hasn't finished playing out, not a coiled spring

→ vs aggressive: 'Every pullback was a buying opportunity' is survivor bias applied retroactively; prior pullbacks occurred well below prior all-time highs; the current 12-day post-peak 10% decline has no historical confirmation as a buying opportunity

→ vs aggressive: Proposed entry at 1160 with 38-dollar stop (exactly one ATR) creates high probability of stop-out on any normal volatile day in current regime; this generates commissions, not returns, and leaves capital chasing a reclaim at higher prices

→ vs aggressive: Forward PEG of 0.48 using consensus EPS of 47.23 ignores that estimates get revised DOWN when binary risks materialize; a 10% cut to 2027 GLP-1 revenue estimates drops forward EPS to ~42, making the stock 20% more expensive at the same price

→ vs aggressive: Best-in-class fundamentals (47.7% revenue growth, 54% operating margins) do not protect against valuation risk; 'great company' is not synonymous with 'great stock at any price'—this is a category error

→ vs aggressive: Capex exceeding operating FCF funded by debt creates second-order risk; if GLP-1 demand softens, massive manufacturing capacity becomes stranded debt; net debt rising 10B in one year is a balance sheet risk that deserves acknowledgment

→ vs aggressive: Higher-for-longer rates compress present value of long-dated pipeline cash flows for growth compounder; LLY's value sits in 2028+ cash flows, making this a structural headwind, not a tailwind

→ vs aggressive: Macro report explicitly shows risk-off signals (US equities falling, Treasury yields jumping, crude rising, gold topping, crypto falling) tied to Iran hostilities; ignoring active geopolitical risk in favor of 'quality compounds' framing is reckless

→ vs aggressive: Sentiment report explicitly states confidence is LOW because retail is NOT OBSERVED; calling this 'consensus bullish' is factually incorrect—it is thin institutional positioning that could unwind quickly

→ vs aggressive: Labeling patient capital preservation as 'fear' is rhetoric, not analysis; waiting for structurally supported entries (200 SMA, MACD reversal) versus adding into elevated-vol noise is the asymmetric setup, not the 50/50 coin flip being proposed

HOLD current exposure; add 3-4% in $1,100-$1,125 zone with technical confirmation; supplemental healthcare exposure via ETF

• Primary add zone: $1,100-$1,125 (closer to current price, above 200 SMA at $1,057)
• Secondary add zone: $1,150-$1,180 if technical stabilization confirmed (MACD histogram stops declining, RSI doesn't break 40)
• Stop placement: $1,050 (below 200 SMA, approximately 2 ATR of room)
• Position sizing: 3-4% on first add, additional 2-3% in secondary zone, capped at 5-7% total new exposure
• Trigger conditions: RSI curling above 45 OR MACD histogram slowing decline before adding
• Recommend supplementing with diversified healthcare exposure (XBI or healthcare ETF) to manage single-name concentration risk
• Balance sheet: $11 billion annual free cash flow, leverage manageable despite debt rising from $34B to $48B
• Defensive quality: beta 0.506; FDA label expansion (cardiovascular outcomes) provides payer negotiation ammunition
• Macro backdrop: 89% odds of zero Fed cuts in 2026, sticky inflation, geopolitical risk-off environment

→ vs aggressive: Survivor bias in comparing current pullback to prior pullbacks that occurred below all-time highs; current pullback is 12 days post fresh ATH at $1,292

→ vs aggressive: PEG math of 0.48 treats consensus estimates as facts; estimates can be revised down 10% if payer coverage contracts, making PEG 20% more expensive

→ vs aggressive: Proposed stop at $1,122 is exactly 1 ATR ($38.70) away, creating high probability of being stopped out on routine volatility in elevated-vol regime

→ vs aggressive: Adding 3-5% during confirmed downtrend with MACD bearish cross, RSI not oversold, and price below 10 EMA, 50 SMA, and VWMA is fighting momentum

→ vs aggressive: Novo already launched oral Wegovy in Germany; competitor timing uncertainty not priced into 2-3 year window assumption

→ vs conservative: Waiting for $1,050-$1,090 may mean missing 20-30% move if stock rips on positive catalysts (Merida close Q4, Zepbound data, payer negotiation signals)

→ vs conservative: $1,000 stop is 14% below current price, excessive if long-term uptrend is intact, creating barely 1:1 risk/reward to $1,350 target

→ vs conservative: Price +9.7% above 200 SMA with 200 SMA as stair-stepping support throughout 2026 indicates tactical pullback, not structural breakdown

→ vs conservative: $11B annual FCF with healthy EBITDA-to-interest coverage and current ratio of 1.36 means balance sheet deterioration is manageable trade-off, not major red flag

→ vs conservative: FDA cardiovascular outcomes label expansion provides structural moat widening against payer risk, insufficiently acknowledged in bear case